180 related articles for article (PubMed ID: 16139970)
1. Are all aciclovir cream formulations bioequivalent?
Trottet L; Owen H; Holme P; Heylings J; Collin IP; Breen AP; Siyad MN; Nandra RS; Davis AF
Int J Pharm; 2005 Nov; 304(1-2):63-71. PubMed ID: 16139970
[TBL] [Abstract][Full Text] [Related]
2. Assessing equivalence of innovator and generic formulations of betamethasone dipropionate cream and ointment.
Sequira J; Berardi M; Chan TM; Letarte J; Malchow R; Pramanick B; Wolkoff HN
Clin Ther; 1991; 13(6):687-94. PubMed ID: 1790543
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous Pharmacokinetics of Acyclovir Cream 5% Products: Evaluating Bioequivalence with an In Vitro Permeation Test and an Adaptation of Scaled Average Bioequivalence.
Shin SH; Rantou E; Raney SG; Ghosh P; Hassan H; Stinchcomb A
Pharm Res; 2020 Oct; 37(10):210. PubMed ID: 33001286
[TBL] [Abstract][Full Text] [Related]
4. Effect of finite doses of propylene glycol on enhancement of in vitro percutaneous permeation of loperamide hydrochloride.
Trottet L; Merly C; Mirza M; Hadgraft J; Davis AF
Int J Pharm; 2004 Apr; 274(1-2):213-9. PubMed ID: 15072797
[TBL] [Abstract][Full Text] [Related]
5. In vivo quantification of acyclovir exposure in the dermis following iontophoresis of semisolid formulations.
Shukla C; Friden P; Juluru R; Stagni G
J Pharm Sci; 2009 Mar; 98(3):917-25. PubMed ID: 18623192
[TBL] [Abstract][Full Text] [Related]
6. In vitro percutaneous penetration of acyclovir from solvent systems and Carbopol 971-P hydrogels: influence of propylene glycol.
Díez-Sales O; Garrigues TM; Herráez JV; Belda R; Martín-Villodre A; Herráez M
J Pharm Sci; 2005 May; 94(5):1039-47. PubMed ID: 15793815
[TBL] [Abstract][Full Text] [Related]
7. Use of an in vitro human skin permeation assay to assess bioequivalence of two topical cream formulations containing butenafine hydrochloride (1%, w/w).
Mitra A; Kim N; Spark D; Toner F; Craig S; Roper C; Meyer TA
Regul Toxicol Pharmacol; 2016 Dec; 82():14-19. PubMed ID: 27816671
[TBL] [Abstract][Full Text] [Related]
8. A comparison of the physicochemical properties and a sensory test of Acyclovir creams.
Inoue Y; Furuya K; Matumoto M; Murata I; Kimura M; Kanamoto I
Int J Pharm; 2012 Oct; 436(1-2):265-71. PubMed ID: 22750948
[TBL] [Abstract][Full Text] [Related]
9. Utilization of nanotechnology to enhance percutaneous absorption of acyclovir in the treatment of herpes simplex viral infections.
Al-Subaie MM; Hosny KM; El-Say KM; Ahmed TA; Aljaeid BM
Int J Nanomedicine; 2015; 10():3973-85. PubMed ID: 26109856
[TBL] [Abstract][Full Text] [Related]
10. Influence of formulation on the in vitro transdermal penetration of flutrimazole.
Ramis J; Conte L; Segado X; Forn J; Lauroba J; Calpena A; Escribano E; Domenech J
Arzneimittelforschung; 1997 Oct; 47(10):1139-44. PubMed ID: 9368709
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the in vitro skin permeation of antiviral drugs from penciclovir 1% cream and acyclovir 5% cream used to treat herpes simplex virus infection.
Hasler-Nguyen N; Shelton D; Ponard G; Bader M; Schaffrik M; Mallefet P
BMC Dermatol; 2009 Apr; 9():3. PubMed ID: 19341466
[TBL] [Abstract][Full Text] [Related]
12. Application of an Optimized Tape Stripping Method for the Bioequivalence Assessment of Topical Acyclovir Creams.
Nallagundla S; Patnala S; Kanfer I
AAPS PharmSciTech; 2018 May; 19(4):1567-1573. PubMed ID: 29484615
[TBL] [Abstract][Full Text] [Related]
13. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
[TBL] [Abstract][Full Text] [Related]
14. Comparison of in vitro release rates of acyclovir from cream formulations using vertical diffusion cells.
Nallagundla S; Patnala S; Kanfer I
AAPS PharmSciTech; 2014 Aug; 15(4):994-9. PubMed ID: 24824173
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of creams and ointments as suitable formulations for peldesine.
Viegas TX; Van Winkle LL; Lehman PA; Franz SF; Franz TJ
Int J Pharm; 2001 May; 219(1-2):73-80. PubMed ID: 11337167
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of barrier creams against sulphur mustard: (II) In vivo and in vitro studies using the domestic white pig.
Chilcott RP; Dalton CH; Ashley Z; Allen CE; Bradley ST; Maidment MP; Jenner J; Brown RF; Gwyther RJ; Rice P
Cutan Ocul Toxicol; 2007; 26(3):235-47. PubMed ID: 17687688
[TBL] [Abstract][Full Text] [Related]
17. Failure of topical acyclovir in ointment to penetrate human skin.
Freeman DJ; Sheth NV; Spruance SL
Antimicrob Agents Chemother; 1986 May; 29(5):730-2. PubMed ID: 3729337
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of acyclovir in rabbit skin after i.v.-bolus, ointment, and iontophoretic administrations.
Stagni G; Ali ME; Weng D
Int J Pharm; 2004 Apr; 274(1-2):201-11. PubMed ID: 15072796
[TBL] [Abstract][Full Text] [Related]
19. Development of performance matrix for generic product equivalence of acyclovir topical creams.
Krishnaiah YS; Xu X; Rahman Z; Yang Y; Katragadda U; Lionberger R; Peters JR; Uhl K; Khan MA
Int J Pharm; 2014 Nov; 475(1-2):110-22. PubMed ID: 25089511
[TBL] [Abstract][Full Text] [Related]
20. Assessment of topical corticosteroid activity using the vasoconstriction assay in healthy volunteers.
Görne RC; Greif C; Metzner U; Wigger-Alberti W; Elsner P
Skin Pharmacol Physiol; 2007; 20(3):133-40. PubMed ID: 17191036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
